SCHEMBL5651574

SCHEMBL5651574

CCc1cc(-c2oncc2-c2ccc(OC)cc2)c(OC)cc1OC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.82
KMT2A Q03164 5/20 0.82
GAA P10253 1/20 0.44
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PTGS2 P35354 1/20 0.38
TUBB4A P04350 2/20 0.37
TUBB P07437 2/20 0.37
TUBA3C P0DPH7 2/20 0.37
TUBA1B P68363 2/20 0.37
TUBA4A P68366 2/20 0.37
TUBB4B P68371 2/20 0.37
TUBB3 Q13509 2/20 0.37
TUBB2A Q13885 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474303 0.91 KMT2A (0.72) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL1167690 0.90 KMT2A (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL30078294 0.90 KMT2A (1.00) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL5651180 0.89 MEN1 (0.65) MEN1KMT2AMAPTMAPK1ATM
SCHEMBL5651833 0.87 MEN1 (0.67) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL1168174 0.86 MEN1 (0.61) MEN1KMT2AALDH1A1PTGS2BACE1
SCHEMBL1167880 0.82 KMT2A (0.66) MEN1KMT2AGAAMAPTHSP90AA1
SCHEMBL5653865 0.81 MEN1 (0.84) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL1167473 0.81 MEN1 (0.55) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL1168581 0.80 MEN1 (0.54) MEN1KMT2AMAPTHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US claimed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US claimed
US-7250432-B2 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-31 US disclosed
WO-2006126751-A1 NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2006-11-30 WO disclosed
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131036-A1 Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers UACA, SQLE, ALDH1A2 MEN1 3914/4885KMT2A 4307/4885GAA 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.